Theralase Releases Q222 Interim Financial Statements

TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) — Theralase

Related Keywords

United States ,Canada ,Toronto ,Ontario ,Canadian ,Arkady Mandel ,Vera Madzarevic ,Company Photo Dynamic Compounds ,Good Laboratory Practices ,Collaborative Research Agreement ,Development Expenses ,Technologies Inc ,Public Health Agency Of Canada ,Postmedia Network Inc ,National Microbiology Laboratory ,Venture Exchange ,Regulation Services Provider ,Financial Statements ,Photodynamic Compounds ,Postmedia Network ,Street East ,Consolidated Statements ,Through Designation ,Fast Track Designation ,Fast Track ,Break Through Designation ,Accelerated Approval ,Priority Review ,Clinical Study Sites ,Therapeutic Dose ,Evaluable Patients ,Muscle Invasive Bladder Cancer ,Interim Chief Executive Officer ,Chief Scientific ,Glio Blastoma Multiforme ,Non Small Cell Lung Cancer ,Public Health Agency ,Dynamic Compound Inactivation ,Study Sites ,Photo Dynamic Compounds ,More Information ,Chief Financial ,